RESUMO
PURPOSE: In adult women, most malignant ovarian tumors are epithelial in origin. The use of intra-operative frozen section to distinguish between benign and malignant histology is reliable in guiding operative decision-making to determine the extent of surgical staging required. Pediatric and adolescent patients with ovarian masses have a much different spectrum of pathology with most tumors arising from germ cell precursors. This review was undertaken to assess the concordance between the intra-operative frozen section and the final diagnosis as an aid to guide extent of surgical staging in a group of pediatric and adolescent patients with malignant ovarian germ cell tumors. METHODS: Records of patients aged 0 to 20 years with malignant ovarian germ cell tumors enrolled on Children's Oncology Group study AGCT0132 were reviewed. Pathology reports from patients who had both intra-operative frozen section diagnosis and final paraffin section diagnosis were compared using descriptive statistics. By inclusion criteria for the study, all patients had a final diagnosis of malignancy with required yolk sac tumor, choriocarcinoma or embryonal carcinoma histology. Available central review of pathology final paraffin section slides were compared with final institution pathology reports. RESULTS: Of 131 eligible patients with ovarian germ cell tumors, 60 (45.8%) had both intra-operative frozen section and final paraffin section diagnoses available. Intra-operative frozen section diagnoses were classified as: incorrect diagnosis of benign tumor (13.3%), confirmation of malignancy (61.7%), immature teratoma (16.7%), germ cell tumor not otherwise specified (5%) and no diagnosis provided (3.3%). Intra-operative frozen section was incorrect in 23 of 60 (38.3%) patients evaluated. Central pathology review was concordant with the final institution pathology diagnosis in 76.3% of patients. Central pathology review identified additional germ cell tumor components in 23.7% of patients. CONCLUSIONS: In pediatric and adolescent patients with a confirmed final diagnosis of ovarian germ cell malignancy, intra-operative frozen section diagnosis is not reliable to inform the extent of surgical staging required. Central review by an expert germ cell tumor pathologist provides important additional information to guide therapy.
Assuntos
Neoplasias Embrionárias de Células Germinativas , Neoplasias Ovarianas , Adolescente , Adulto , Criança , Feminino , Secções Congeladas , Humanos , Neoplasias Embrionárias de Células Germinativas/diagnóstico , Neoplasias Embrionárias de Células Germinativas/cirurgia , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/cirurgia , Parafina , Estudos Retrospectivos , Neoplasias TesticularesRESUMO
Management of spinal cord compression from a primary paraspinal endodermal sinus tumor (EST) is described. A 17-month-old child presented for treatment with near-complete paraplegia secondary to spinal cord compression from a primary paraspinal EST. The child was treated with cisplatin-based chemotherapy without laminectomy or radiation therapy. Rapid resolution of symptoms was observed. The child had an excellent tumor response and complete neurologic recovery with no sequelae. Chemotherapy alone is an alternative to laminectomy or radiation therapy in the management of epidural cord compression from EST, even when the cord compression is severe.
Assuntos
Tumor do Seio Endodérmico/complicações , Compressão da Medula Espinal/etiologia , Neoplasias da Medula Espinal/complicações , Tumor do Seio Endodérmico/tratamento farmacológico , Humanos , Lactente , Masculino , Neoplasias da Medula Espinal/tratamento farmacológicoRESUMO
OBJECTIVE: To investigate the hypothesis that intracellular, dominant-negative mutations of the growth hormone receptor (GHR) exist in children with idiopathic short stature (ISS) and partial growth hormone insensitivity (GHI). SUBJECTS: We studied 31 children aged 4.55-13.14 years with ISS (height = -1.8 standard deviation scores, UK standards 1990). GH provocation tests (glucagon 15 microg kg-1 i.m.) excluded GH deficiency in all subjects. Serum IGF-I levels were below the 50th centile for age in all subjects and below the 10th centile in 64.5% of cases. GH binding protein levels were normal in the 24 subjects in whom it was measured (mean 25.2%; range 10-42.6%). METHODS: Exons 9 and 10 of the GHR were amplified by PCR from leucocyte-derived DNA. Samples were directly sequenced on the ABI 377 DNA analyser using the - 21 M13 dye primer cycle sequencing protocol for optimum heterozygote detection. RESULTS: No abnormalities were detected in exon 9 which encodes the proline-rich box 1 motif. In exon 10 two sequence variants were found; a heterozygous, single base alteration (TCT to TCC) in codon 325 which does not change the amino acid sequence in one patient, and the L526I variant in 24 subjects. L526I is a conservative amino acid change and had an allele frequency of 0.53 in our patients, which is similar to that reported in a control population. CONCLUSIONS: The apparent partial growth hormone insensitivity in this group of idiopathic short-stature subjects is not related to heterozygous, dominant-negative variants of the intracellular signalling domain of the GHR. Hence it is likely that other genetic and environmental factors may be involved.